---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000050"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:46:01.487596+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Autolus appoints Mike Bonney as Chair and Ravi Rao as director; John Johnson resigns effective April 1, 2024

## Summary
- John H. Johnson steps down as Chairman and Non-Executive Director; departure not due to disagreements.
- Mike Bonney appointed Chairman of the Board; over 30 years biotech experience, formerly CEO of Cubist Pharmaceuticals.
- Ravi Rao, M.D. appointed Non-Executive Director; current CMO of Sitryx and previous CMO at Oxford Biomedica.
- Board changes effective April 1, 2024; Bonney and Rao receive annual retainers and initial option awards.
- Press release notes recent FDA acceptance of BLA for obe-cel in r/r adult B-cell ALL as key company milestone.

## SEC filing metadata
- accession: 0001730463-24-000050
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/0001730463-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/autl-20240326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000050
- JSON: https://secwatch.observer/filing/0001730463-24-000050.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000050.txt

## Key facts
- Executive change
  John Johnson resigned as Chairman of the Board at Autolus Therapeutics plc.
  - Action: resigned
  - Role: Chairman of the Board
  source text: On March 26, 2024, John Johnson notified Autolus Therapeutics plc (the “Company”) of his resignation from the Board of Directors (the “Board”) of the Company, effective April 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/0001730463-24-000050-index.htm
- Executive change
  Michael Bonney was appointed as Chairman of the Board at Autolus Therapeutics plc.
  - Action: appointed
  - Role: Chairman of the Board
  source text: appointed Michael W. (“Mike”) Bonney to serve as a Class II director of the Company and as Chair of the Board, effective April 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/0001730463-24-000050-index.htm
- Executive change
  Ravi Rao was appointed as Non-Executive Director at Autolus Therapeutics plc.
  - Action: appointed
  - Role: Non-Executive Director
  source text: appointed Ravi M. Rao, M.D. to serve as a Class I director of the Company and member of the Research and Development Committee, effective April 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/0001730463-24-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.